IDiyas

For the Inventor, By the Inventor

Harlow, United Kingdom

Gerard Martin Paul Giblin

USPTO Granted Patents = 16

 

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 42(Granted Patents)


Location History:

  • Hertfordshire, GB (2005)
  • The Frythe, GB (2007)
  • Welwyn, GB (2005 - 2010)
  • Harlow, GB (2008 - 2012)

Company Filing History:

goldMedal14 out of 1,168 
 
Glaxo Group Limited
 patents
silverMedal2 out of 2,198 
 
Smithkline Beecham Corporation
 patents

Years Active: 2005-2012

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 8324254 - Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists (2012-12-04),
2. 8252833 - [object Object] (2012-08-28),
3. 8207213 - Benzoisoindole derivatives for the treatment of pain (2012-06-26),
4. 8026270 - Benzo [F] isoindoles as EP4 receptor agonists (2011-09-27),
5. 7759369 - Pyridine compounds for the treatment of prostaglandin mediated diseases (2010-07-20),
6. 7732622 - Naphthalene derivatives (2010-06-08),
7. 7718689 - Benzoisoindole derivatives and their use as EP4 receptor ligands (2010-05-18),
8. 7635701 - Pyrimidine derivatives and their use as CB2 modulators (2009-12-22),
9. 7589206 - Pyrrolopyridine derivatives (2009-09-15),
10. 7446222 - Phenyl compounds (2008-11-04),
11. 7288564 - Indole derivatives (2007-10-30),
12. 7232821 - (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives (2007-06-19),
13. 7173047 - Benzo (f) insoindol derivatives and their use as ep4 receptor ligands (2007-02-06),
14. 7166631 - Benzo[f]isoindole derivatives with affinity to the EP4 receptor (2007-01-23),
15. 6924297 - Naphathalene derivatives which bind to the EP4 receptor (2005-08-02),

Title: The Innovative Contributions of Gerard Martin Paul Giblin

Introduction

Gerard Martin Paul Giblin is a notable inventor based in Harlow, GB. He has made significant contributions to the field of pharmacology, holding a total of 16 patents. His work primarily focuses on developing compounds with therapeutic applications.

Latest Patents

One of Giblin's latest patents involves oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists. This invention provides compounds of a specific formula, along with their salts, that exhibit pharmacological activity. The patent details processes for preparing these compounds, pharmaceutical compositions containing them, and their applications in treating various disorders mediated by S1P1 receptors.

Career Highlights

Throughout his career, Giblin has worked with prominent companies in the pharmaceutical industry, including Glaxo Group Limited and SmithKline Beecham Corporation. His expertise in drug development has positioned him as a valuable asset in the field.

Collaborations

Giblin has collaborated with notable professionals such as Neil Derek Miller and Mark Patrick Healy. These partnerships have likely contributed to the advancement of his innovative projects.

Conclusion

Gerard Martin Paul Giblin's work exemplifies the impact of innovation in pharmacology. His patents and collaborations reflect a commitment to advancing medical science through inventive solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…